130 related articles for article (PubMed ID: 35481444)
1. Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Villasboas JC; Paludo J; Markovic SN
Leuk Lymphoma; 2022 Oct; 63(10):2436-2443. PubMed ID: 35481444
[TBL] [Abstract][Full Text] [Related]
2. Infused Autograft Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched Case-Control Study.
Porrata LF; Burgstaler EA; Winters JL; Jacob E; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Villasboas J; Paludo J; Markovic SN
Transplant Cell Ther; 2021 Sep; 27(9):769.e1-769.e8. PubMed ID: 34091071
[TBL] [Abstract][Full Text] [Related]
3. EBV
Liu H; Xu-Monette ZY; Tang G; Wang W; Kim Y; Yuan J; Li Y; Chen W; Li Y; Fedoriw GY; Zhu F; Fang X; Luedke C; Medeiros LJ; Young KH; Hu S
Histopathology; 2022 Feb; 80(3):575-588. PubMed ID: 34637146
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.
Bliven SP; Shea L; Bal S; Goyal G; Mehta A; Narkhede M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):825-834. PubMed ID: 35869021
[TBL] [Abstract][Full Text] [Related]
5. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
6. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma.
Porrata LF; Litzow MR; Inwards DJ; Gastineau DA; Moore SB; Pineda AA; Bundy KL; Padley DJ; Persky D; Ansell SM; Micallef IN; Markovic SN
Bone Marrow Transplant; 2004 Feb; 33(3):291-8. PubMed ID: 14676784
[TBL] [Abstract][Full Text] [Related]
7. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study.
Porrata LF; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Gastineau DA; Litzow MR; Winters JL; Markovic SN
Biol Blood Marrow Transplant; 2008 Jul; 14(7):807-16. PubMed ID: 18541201
[TBL] [Abstract][Full Text] [Related]
8. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
Cinar M; Rosenfelt F; Rokhsar S; Lopategui J; Pillai R; Cervania M; Pao A; Cinar B; Alkan S
Leuk Res; 2015 Jul; 39(7):730-8. PubMed ID: 25916698
[TBL] [Abstract][Full Text] [Related]
9. Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Kim A; Stevenson P; Cassaday RD; Soma L; Fromm JR; Gopal AK; Smith SD; Till B; Lynch RC; Ujjani C; Shadman M; Warren EH; Menon M; Russell K; Tseng YD
Pract Radiat Oncol; 2020; 10(1):44-52. PubMed ID: 31585205
[TBL] [Abstract][Full Text] [Related]
10. High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.
Zhang J; Weng Z; Huang Y; Li M; Wang F; Wang Y; Rao H
Am J Surg Pathol; 2020 Dec; 44(12):1602-1611. PubMed ID: 32991338
[TBL] [Abstract][Full Text] [Related]
11. AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Miyaoka M; Kikuti YY; Carreras J; Itou A; Ikoma H; Tomita S; Shiraiwa S; Ando K; Nakamura N
Pathol Int; 2022 Jan; 72(1):35-42. PubMed ID: 34727403
[TBL] [Abstract][Full Text] [Related]
12. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study.
Laude MC; Lebras L; Sesques P; Ghesquieres H; Favre S; Bouabdallah K; Croizier C; Guieze R; Drieu La Rochelle L; Gyan E; Chin R; Aurran-Schleinitz T; Marouf A; Deau-Fischer B; Coppo P; Malot S; Roussel X; Chauchet A; Schwarz M; Bescond C; Lamy de la Chapelle T; Bussot L; Carras S; Burlet B; Rossi C; Daniel A; Morschhauser F; Subtil F; Michallet AS
Am J Hematol; 2021 Mar; 96(3):302-311. PubMed ID: 33306213
[TBL] [Abstract][Full Text] [Related]
14. Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma.
Porrata LF; Burgstaler EA; Winters JL; Jacob EK; Gastineau DA; Suman VJ; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nevala W; Markovic SN
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1017-1023. PubMed ID: 26826432
[TBL] [Abstract][Full Text] [Related]
15. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma.
Huang S; Nong L; Wang W; Liang L; Zheng Y; Liu J; Li D; Li X; Zhang B; Li T
Diagn Pathol; 2019 Jul; 14(1):81. PubMed ID: 31315646
[TBL] [Abstract][Full Text] [Related]
17. Infusion of autograft natural killer cell/CD14
Kansagra A; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Hogan WJ; Markovic SN; Porrata LF
Bone Marrow Transplant; 2018 Feb; 53(2):146-154. PubMed ID: 29035394
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.
Kim H; Kim HJ; Kim SH
Ann Lab Med; 2020 Sep; 40(5):361-369. PubMed ID: 32311849
[TBL] [Abstract][Full Text] [Related]
19. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation for diffuse large B-cell lymphoma having 8q24/MYC rearrangement in Japan.
Takahashi T; Suzuki R; Yamamoto G; Nakazawa H; Kurosawa M; Kobayashi T; Okada M; Akasaka T; Kim SW; Fukuda T; Ichinohe T; Atsuta Y; Suzumiya J
Hematol Oncol; 2021 Feb; 39(1):66-74. PubMed ID: 32979280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]